New Insights on Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection: What a 222-Participant Study Found

Official journal of the American Society of Clinical Oncology (2026), this phase iii randomized trial evaluating 222 human participants investigated: The ASCOT phase III trial demonstrated that adjuvant S-1, an oral fluoropyrimidine, improved 3-year overall survival (OS) from 67.6% to 77.1% in patients with resected biliary tract cancer (BTC). When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

To find out, researchers writing in Journal of clinical oncology : official journal of the American Society of Clinical Oncology conducted a phase iii randomized trial evaluating 222 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

Treatment effects were generally consistent across subgroups. These findings confirm a sustained survival benefit with adjuvant S-1 and support its role as a standard treatment for resected BTC. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.